Nexus Life Science Partners Mergers and Acquisitions Summary

Growth Capital Firm Profile

Nexus Life Science Partners’ most common sectors for investment arelife science (72%) and medical products (29%) . The Firm’s most common investment types include venture (43%) and buyout (lbo, mbo, mbi) (29%). In total, Nexus Life Science Partners has invested in 5 US states.

In the last 3 years, Nexus Life Science Partners has exited 1 company. The Firm’s most common exit type is trade sale (46%). Nexus Life Science Partners’ largest (disclosed) exit occurred in 2005 when it sold Abgenix for $2.2B.

Join Mergr to view Nexus Life Science Partners’ full profile and discover more small growth capital firm investors just like it.

M&A Summary

  • M&A Total Activity29
    • M&A Buy Activity7
    • M&A Sell Activity22
  • Total Sectors Invested 2
  • Total Countries Invested 1
  • M&A Buy/Sell Connections 14

Nexus Life Science Partners

424 West, 33rd Street, Suite 520,
New York, New York 10001
United States
www.merlinnexus.com
invest@merlinnexus.com

Nexus Life Science Partners is a private equity firm that targets private and public healthcare companies located within the United States and around the world. The Firm's focus is on the growth segments of the healthcare industry. In particular, Nexus looks for product-driven life sciences companies developing breakthrough therapeutics for clinical needs, positively altering disease course and associated costs. The firm seeks for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital. Nexus Life Science Partners was formed in 2001, and is based in New York, New York.


Investment Criteria

Sectors of Interest: Healthcare Services, Life Science, Medical Products

Target Transaction Types: Growth Capital, Stake Purchase

Geographic Preferences: East US, Midwest US, South US, West US

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value - -

M&A Summary

Buy vs Sell

Year ≤ '18 '19 '20 '21 '22 '23 T
Buy (0.0/yr) # 7 - - - - - 7
Sell (0.2/yr) # 21 - 1 - - - 22
vol $6.3B $6.3B
  29

Most Recent M&A

Company Date Value Type
Sunesis Pharmaceuticals, Inc. 2020-11-30 - Merger
South San Francisco, California · www.sunesis.com
Gentium SpA 2013-12-20 1.0B USD Trade Sale
Villa Guardia, Italy · www.gentium.it
Cymabay Therapeutics, Inc. 2013-11-29 - IPO
Newark, California · www.cymabay.com
Aryx Therapeutics, Inc. 2013-05-01 - Bankruptcy
Fremont, California · www.aryx.com
Calypso Medical Technologies, Inc. 2011-09-19 10M USD Trade Sale
Seattle, Washington · www.calypsomedical.com
Salient Surgical Technologies, Inc. 2011-07-07 525M USD Trade Sale
Portsmouth, New Hampshire · www.salientsurgical.com
Orthovita, Inc. 2011-05-16 316M USD Trade Sale
Malvern, Pennsylvania · www.orthovita.com
Gemin X Biotechnologies, Inc. 2011-03-22 225M USD Trade Sale
Montreal, Quebec · www.geminx.com
Dov Pharmaceutical, Inc. 2010-07-19 - Trade Sale
Somerset, New Jersey · www.dovpharm.com
Aveo Pharmaceuticals, Inc. 2010-03-18 - IPO
Boston, Massachusetts · www.aveopharma.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science - - 5 (71%) -
Medical Products - - 2 (29%) -
Total - - 7 -

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States - - 7 (100%) -
  California - - 3 (43%) -
  Texas - - 1 (14%) -
  Pennsylvania - - 1 (14%) -
  Colorado - - 1 (14%) -
  Washington - - 1 (14%) -
Total - - 7 -

Acquisitions by Deal Type

Type Current # Value All-time # Value
Venture - - 3 (43%) -
Buyout (LBO, MBO, MBI) - - 2 (29%) -
Divestiture - - 1 (14%) -
PIPE - - 1 (14%) -
Total - - 7 -

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 10 (45%) 5.0B (94%)
IPO 6 (27%) -
Trade Sale 4 (18%) 345M (6%)
Bankruptcy 1 (5%) -
Merger 1 (5%) -
Total 22 $5.3B

Deal Values

sell # Total
> $1B 3 $4.2B
$100M to $1B 5 $2.1B
< $100M 1 $10M
TOTAL $6.3B
Largest Abgenix, Inc.
$2.2B (2005-12-14)

M&A Connections

Deals
Acquired from
Strategic(s)
14%
1 (14%)
Exited to
Strategic(s)
50%
11 (50%)

FAQ

When was Nexus Life Science Partners founded?

Nexus Life Science Partners was founded in 2001.

What type of investor is Nexus Life Science Partners?

Nexus Life Science Partners is a growth capital firm.

Where is Nexus Life Science Partners headquartered?

Nexus Life Science Partners is headquartered in New York, New York.

 Subscribe to unlock this and 197,042
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.5K Private Equity Firms
  • 188K M&A Transactions
  • 193K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.5K M&A Advisors
    (Investment Banks and Law Firms)
  • 74K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.